Guidelines for prophylaxis of cytomegalovirus disease in bone marrow transplant patients

Annals of Pharmacotherapy

Volumn 30, Issue 12, 1996, Pages 1483-1486

  Badas, Anna ^a,b   Stoukides, Cheryl A ^c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c Medical Outcomes Management Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COLONY STIMULATING FACTOR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; PLACEBO;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL;

EID: 0030449248     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001218     Document Type: Article

References (26)

1. Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990:12(suppl 7):S776-92.
2. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995;123:205-15.
3. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-7.
4. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA, et al. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324:1005-11.
5. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993;118:179-84.
6. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8.
7. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan CM. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
8. Drew WL, Miner RC, Busch DF, Follansbee SE, Gillett J, Mehalko SG, et al. Prevalence of resistance in patients receiving ganciclovir for serious cylomegalovirus infection. J Infect Dis 1991;163:716-9.
9. Van der Bij W, Torensma R, van Son WJ, Anema J, Schirm J, Tegzess AM, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988;25:179-88.
10. Jiwa MM, Van Gemert GW, Raap AK, Van de Rijke FM, Mulder A, Lens PF, et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction. Transplantation 1989;48:72-6.
11. Gerna G, Zipeto D, Parea M, Revello MG, Silini E, Percivalle E, et al. Monitoring of human cylomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 1991;164:488-98.
12. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:70-5.
13. Prentice HG, Gluckman E, Powles RL. Ljungman P, Milpied NJ, Fernandez Ranada M, et al. Impact of long-term acyciovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749-53.
14. Selby PJ, Powles RL, Easton D. The prophylactic use of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989;59:434-8.
15. Lundgren G, Wilczek H, Lonnqvist B. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis 1985;47(suppl):137-44.
16. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992;166:473-9.
17. Bacigalupo A, Tedone E, Van Lint MT, Trespi G, Lonngren M, Sanna MA, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994;13:783-8.
18. Bacigalupo A, Van Lint MT, Tedone E, Moro F, Sanna MA, Longren M, et al. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant 1994;13:753-8.
19. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 1994;13:499-510.
20. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cylomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-10.
21. Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991;164:483-7.
22. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987;106:12-8.
23. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323:705-12.
24. Duncan SR, Paradis IL, Dauber JH. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis 1992;146:1213-5.
25. Nakazato PZ, Burns W, Moore P. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and ganciclovir. Transplant Proc 1993;25:1935-7.
26. Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994;120:143-58.